-

Beasley Allen/Ashcraft & Gerel Law Firms: Talc MDL Leadership Rejects Johnson & Johnson’s Second Attempt to Abuse Bankruptcy Process

TRENTON, N.J.--(BUSINESS WIRE)--This week, Johnson & Johnson announced what the company says is a resolution of tens of thousands of talc ovarian cancer and mesothelioma claims.

The following statement is a reaction from attorneys Leigh O’Dell of the Beasley Allen Law Firm and Michelle Parfitt of Ashcraft & Gerel, co-chairs of the plaintiffs’ steering committee in the federal court multidistrict litigation of these cases:

J&J’s arrogance is boundless, and its mockery of the court system demonstrates a callous, bullying mindset. There are no tactics too underhanded for the company to use to try to avoid paying reasonable compensation to these cancer victims.

The talc “settlement” being touted by J&J and the media is NOT a settlement. It is an illusory proposal for a bankruptcy plan, yet another attempt by J&J to misuse the bankruptcy system. All 14 members of the plaintiffs’ steering committee reject this proposal.

In fact, the terms are considerably worse than a proposal that we and other firms representing ovarian cancer victims rejected last June, at a time when it appeared that all plaintiffs could be stuck in bankruptcy court for years. Since then, the Third Circuit Court of Appeals set aside J&J’s bankruptcy and our negotiating position significantly improved.

The settlement that J&J is now trying to impose on plaintiffs, with the aid of a small number of firms handling talc cases, includes:

  • all current and future ovarian cancer victims
  • all current and future mesothelioma victims
  • all attorney general actions for all states, and
  • all other talc-related claims, including claims by medical cost insurers against J&J.

While J&J’s proposed $8.9 billion offer sounds like a lot of money, it is not enough when you consider the terms of the proposal. This settlement proposal would pay far less than $120,000 per case, if that.

The costs of medical care and lost wages alone for ovarian cancer victims approach $500,000. That does not address the pain and suffering nor punitive damages those women and their families have suffered by J&J’s massive and deliberate cover-up of the dangers of its asbestos-laden talc products.

Rest assured, we are vigorously opposing this deal and will continue fighting to get fair compensation for clients. And through a remarkable team effort, we are confident that this ploy by J&J to unfairly force a bad deal will be rebuffed, and we will be able to negotiate a fair one for clients. Alternatively, we will get this second bankruptcy thrown out, just as we did the first, so that we can present clients’ cases before juries again soon.

Contacts

Mark Annick
800.559.4534
mark@androvett.com

Beasley Allen Law Firm and Ashcraft & Gerel


Release Versions

Contacts

Mark Annick
800.559.4534
mark@androvett.com

More News From Beasley Allen Law Firm and Ashcraft & Gerel

Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt

HOUSTON--(BUSINESS WIRE)--Attorneys representing tens of thousands of women with ovarian cancer linked to use of Johnson & Johnson (NYSE:JNJ) talc products say they will immediately seek dismissal of a pre-packaged bankruptcy that the company filed earlier today in Texas. In its filing, the New Jersey-based pharmaceutical giant claims that approximately 83% of those plaintiffs surveyed by the company have agreed to the plan’s terms, a percentage that forms the legal threshold for launching...

Lawyers for Ovarian Cancer Victims Endorse Proposed Texas Two-Step Remedy

NEWARK, N.J.--(BUSINESS WIRE)--The attorneys representing tens of thousands of women in their talc-related ovarian cancer lawsuits against Johnson & Johnson (NYSE:JNJ) are calling for passage of a measure in Congress that would end the ability of solvent companies to use the so-called Texas Two-Step bankruptcy process in order to avoid lawsuit liabilities. The process involves taking a company’s liabilities – in this case, the thousands of talc-ovarian cancer lawsuits – placing them into a...

Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan

PHILADELPHIA--(BUSINESS WIRE)--Lawyers on behalf of tens of thousands of ovarian cancer victims are calling on Johnson & Johnson (NYSE: JNJ) to end its “war of attrition against cancer victims.” “The third time will not be the charm for J&J,” says Andy Birchfield, head of the Mass Torts Litigation Section at the Beasley Allen Law Firm, who has been instrumental in helping to foil the first two attempts at bankruptcy by the half-trillion-dollar company. “Recent developments in the courts...
Back to Newsroom